British experts have warned that red tape is standing in the way of clinical trials and the development of new drugs that can help improve childhood cancer survival rates.
The journal Lancet Oncology reported that new regulations make it more costly and difficult than ever to conduct trials into new medicines.
Experts pointed out that childhood cancer survival rates have risen significantly in the last 30 years, and 78% of children in Britain lived for more than five years after their diagnosis between 2001 and 2005.